Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CUL4A | Q13619 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 3/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.66 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.63 |
| ▸ | ALDH3A1 | P30838 | 7/20 | 0.63 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30403461 | 1.00 | CUL4A (0.68) | CUL4AACHECES1PARK7ALDH1A1 | |
| SCHEMBL22655289 | 0.91 | CUL4A (0.58) | CUL4AACHECES1PARK7ALDH1A1 | |
| SCHEMBL21001752 | 0.87 | ALDH1A1 (0.65) | CUL4AACHECES1PARK7ALDH1A1 | |
| SCHEMBL28026697 | 0.86 | PARK7 (0.53) | CUL4AACHECES1PARK7ALDH1A1 | |
| SCHEMBL22667215 | 0.83 | CES1 (0.62) | CUL4AACHECES1PARK7ALDH1A1 | |
| SCHEMBL30404066 | 0.83 | CES1 (0.62) | CUL4AACHECES1PARK7ALDH1A1 | |
| SCHEMBL31419934 | 0.83 | PARK7 (0.66) | CUL4AACHECES1PARK7ALDH1A1 | |
| SCHEMBL4624674 | 0.83 | CUL4A (0.68) | CUL4AACHECES1PARK7ALDH1A1 | |
| SCHEMBL4292310 | 0.82 | CUL4A (0.62) | CUL4AACHECES1PARK7ALDH1A1 | |
| SCHEMBL22667216 | 0.82 | CUL4A (0.62) | CUL4AACHECES1PARK7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022188045-A1 | METHOD FOR CATALYTIC PREPARATION OF PYRANO[2,3-B]INDOLE-2-ONE COMPOUND | 苏州大学 | 2022-09-15 | — | — | WO | disclosed |
| CN-112961166-B | Catalytic preparation of pyrano [2,3-b]Process for preparing indol-2-one compounds | 苏州大学 | 2022-02-25 | — | — | CN | disclosed |
| US-11160797-B2 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2021-11-02 | — | — | US | disclosed |
| US-20200360357-A1 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360357-A1 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | CUL4A 2848/4885ACHE 2992/4885CES1 2359/4885 |
| US-11160797-B2 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | CUL4A 2848/4885ACHE 2992/4885CES1 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.